Tamoxifen resistance in breast cancer: elucidating mechanisms.
about
Cas proteins: dodgy scaffolding in breast cancerBreast cancer oestrogen independence mediated by BCAR1 or BCAR3 genes is transmitted through mechanisms distinct from the oestrogen receptor signalling pathway or the epidermal growth factor receptor signalling pathwayThe estrogen-responsive Agr2 gene regulates mammary epithelial proliferation and facilitates lobuloalveolar developmentHEF1-aurora A interactions: points of dialog between the cell cycle and cell attachment signaling networksIdentification of Novel Crk-associated Substrate (p130Cas) Variants with Functionally Distinct Focal Adhesion Kinase Binding ActivitiesHuman pregnane X receptor is expressed in breast carcinomas, potential heterodimers formation between hPXR and RXR-alphaProteomics analysis of the estrogen receptor alpha receptosome.CAPER, a novel regulator of human breast cancer progression.Promoting E2F1-mediated apoptosis in oestrogen receptor-α-negative breast cancer cellsDifferential gene expression in tamoxifen-resistant breast cancer cells revealed by a new analytical model of RNA-Seq dataReactivation of the tumour suppressor RASSF1A in breast cancer by simultaneous targeting of DNA and E2F1 methylation.Role of sex hormones in the modulation of cholangiocyte function.Structural insights into selective agonist actions of tamoxifen on human estrogen receptor alpha.Denoising perturbation signatures reveal an actionable AKT-signaling gene module underlying a poor clinical outcome in endocrine-treated ER+ breast cancer.Therapeutic potential of tyrosine kinase inhibitors in breast cancer.Regulation of p130(Cas)/BCAR1 expression in tamoxifen-sensitive and tamoxifen-resistant breast cancer cells by EGR1 and NAB2Changes in endocrine therapy: anastrozole and advanced breast cancer in postmenopausal women.Anticancer actions of lysosomally targeted inhibitor, LCL521, of acid ceramidaseJostling for position: optimizing linker location in the design of estrogen receptor-targeting PROTACs.Pretreatment haemoglobin levels significantly predict the tumour response to primary chemotherapy in human breast cancer.Meta-analysis of trials comparing anastrozole and tamoxifen for adjuvant treatment of postmenopausal women with early breast cancer.Estrogen receptors ER alpha and ER beta in proliferation in the rodent mammary gland.Breast carcinoma cells in primary tumors and effusions have different gene array profiles.Estrogen receptor β isoform 5 confers sensitivity of breast cancer cell lines to chemotherapeutic agent-induced apoptosis through interaction with Bcl2L12.Precancer: sequentially acquired or predetermined?A truncated phosphorylated p130Cas substrate domain is sufficient to drive breast cancer growth and metastasis formation in vivo.Isolated and combined action of tamoxifen and metformin in wild-type, tamoxifen-resistant, and estrogen-deprived MCF-7 cells.Reduced PTEN expression predicts relapse in patients with breast carcinoma treated by tamoxifen.Alternative Splicing in Breast Cancer and the Potential Development of Therapeutic Tools.Design, Synthesis, and Cytotoxicity Evaluation of Novel Griseofulvin Analogues with Improved Water Solubility.
P2860
Q21146639-F4132D1D-231C-41AF-AACC-C05FDF76868AQ21195156-23F8CA8A-531F-4E6A-B30A-307023E81F6BQ24630889-4DB80794-B87A-4868-9D09-E92C068C46D9Q28297459-9E0F0CE4-FDA9-49C0-87E2-6129E6DB0006Q30009201-435611F3-7EAB-470F-ACD2-06BDE5B67AB8Q33345012-502B260E-C121-4089-B62C-46266FAD19E4Q33547007-9FFA307B-900B-4177-831B-BEA25FB9AA51Q33728372-762A5F4D-E023-4545-BD83-059C3464080EQ34006827-D383749C-B951-4835-8B49-53069607AC88Q34356351-6715D8F3-E748-4B54-8DF0-F659C596B7DCQ34517696-D501FED1-353E-4BDF-9869-6F7897BE0CB6Q34992322-33EE4396-0F30-4203-A41E-91079A30C698Q35233145-49F66B28-1B07-40B7-A6F2-91E31787D9ADQ35446364-2ACEB8D7-11A1-4C19-BA0D-52FC558F02F9Q35589209-CF0C10CF-3318-4A56-A634-EA8C9B3785FCQ35836030-E1C9F46B-1410-4FCA-8ADC-9387AD6D52B1Q35990530-7EC7DD38-4EA7-4826-AFA1-0D0E052DDFEFQ36405432-4E578818-B856-47F1-9A43-C9C8F672583BQ36452355-60A61CDC-C1B9-4579-879A-46F69301DF4EQ36648420-B3B87940-48AA-47D9-8C6B-505F4E5FED5FQ36823279-4D90663F-9E02-4E2E-8F95-CF7FF6331639Q37094546-381D695B-271C-49CA-B5F1-6D338273C1F8Q37301296-F10C50EA-CC98-469B-B997-1573F96F3D38Q37382513-6041C573-7910-4631-BF11-DC6C30891095Q37658129-BA9C1C75-52F8-4CBC-95CB-5245718BA55CQ38794970-753BBB4E-4DE4-4AD9-9BDF-3B7F9826670BQ39671678-683224CD-049F-46EA-B43F-B0A4F583C894Q45099758-4A92F21C-5D41-4156-9FA9-412713DC5052Q47110708-FDD953AB-8ACE-4326-BA9E-9E77AEF96CCBQ47703909-0CC96D96-0CA0-4736-86A1-799EB44616F1
P2860
Tamoxifen resistance in breast cancer: elucidating mechanisms.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Tamoxifen resistance in breast cancer: elucidating mechanisms.
@ast
Tamoxifen resistance in breast cancer: elucidating mechanisms.
@en
Tamoxifen resistance in breast cancer: elucidating mechanisms.
@nl
type
label
Tamoxifen resistance in breast cancer: elucidating mechanisms.
@ast
Tamoxifen resistance in breast cancer: elucidating mechanisms.
@en
Tamoxifen resistance in breast cancer: elucidating mechanisms.
@nl
prefLabel
Tamoxifen resistance in breast cancer: elucidating mechanisms.
@ast
Tamoxifen resistance in breast cancer: elucidating mechanisms.
@en
Tamoxifen resistance in breast cancer: elucidating mechanisms.
@nl
P2093
P1433
P1476
Tamoxifen resistance in breast cancer: elucidating mechanisms.
@en
P2093
Brinkman A
Dorssers LC
Foekens JA
Van der Flier S
Veldscholte J
van Agthoven T
P304
P356
10.2165/00003495-200161120-00004
P577
2001-01-01T00:00:00Z
P6179
1021792585